FA, MOCA, sclerotherapy, and open surgery. At 6 months, VenaSeal had
had the highest probability of anatomic success, ranked
ﬁrst in the reduction of the postoperative pain score from
baseline (P ¼ .690), and had had the lowest incidence of
adverse events (P ¼ .650). The 3-year occlusion rate after
CAC treatment was 94.7% (95%